跳至主要内容
临床试验/NCT03345966
NCT03345966Unknown不适用

Validation of Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study

Cairo University1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2017年12月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
18
试验地点
1
主要终点
oral squamous cell carcinoma

研究概览

简要总结

The aim of the current study is to assess the validation of Bmi-1 detection at both protein and molecular levels in oral epithelial dysplasia and oral squamous cell carcinoma as a biomarker for early cancer detection versus biopsy embedded in paraffin blocks.

详细描述

Head and neck squamous cell carcinoma (HNSCC) including oral squamous cell carcinoma (OSCC) has been reported as the sixth most common cause of cancer mortality in the world and the fifth most commonly occurring cancer. Thus a compelling need for investigation of the underlying molecular events associated with OSCC tumorigenesis has emerged for better understanding of such lesion. Moreover, identification of biomarkers for early detection and prediction of prognosis became of extreme importance, as it was reported that early diagnosis has been vital for effective treatment of OSCC and improved the survival rate of OSCC patients.

OSCC may originate from malignant transformation of the normal oral mucosa, as well as from oral potentially malignant lesions (OPMLs) with different degrees of oral epithelial dysplasia (OED). The approach of a step-wise transition from OPMLs to OSCC was well-established, but it could be difficult to predict if and when an OPML would undergo full transformation and resulted in a tumor. Thus, using specific molecular biomarkers able to identify OED lesions with higher potential for malignant transformation would be very beneficial. Unfortunately, up to date there has been no tools available to monitor OED lesions or HNSCC patients for early stages of local recurrences or distant metastases .

Among the recently introduced biomarkers, B-lymphoma Moloney murine leukemia virus insertion region-1 (BMI1), a member of the polycomb group (PcG) genes, was considered to be pivotal in regulating stemness-related genes involved in maintaining the self-renewal ability of stem cells by promoting chromatin modifications. BMI1 was also known to be deregulated in various human types of cancer. Previous studies have revealed the capability of BMI1 to be used as a prognostic marker in gastric, esophageal, nasopharyngeal cancer, prostate, breast, cervical and ovarian cancer, However, the role of BMI1 in maintaining self-renewal and tumorigenicity in HNSCC or HNSCC-derived cancer stem cells (CSCs) remained to be clarified.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Single (Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • In vitro studies.
  • Samples used are oral dysplasia and squamous cell carcinoma.
  • Diagnostic accuracy of Bmi-1 marker on oral dysplasia and SCC.
  • English language published articles only.

排除标准

  • In vivo studies.
  • Studies using any techniques other than immunohistochemistry or PCR.
  • Samples using any carcinoma rather than squamous cell carcinoma.
  • Samples using benign tumors.
  • Samples using sarcomas.

研究组 & 干预措施

Immunohistochemistry

Experimental

In order to provide more precised data on Bmi-1 immunoexpression in OSCC, image analyzer will be used.

The data will be obtained using the software (SIS, Germany), which comprise a light microscope (Olympus B × 60 Japan) capable of performing high speed digital image processing for the purpose of cell measurements. It will be calibrated automatically to convert the measurement units (pixels) produced by image analyzer program into actual micrometer units.

干预措施: Bmi-1 antibody (Diagnostic Test)

Polymerase Chain Reaction PCR

Experimental

Calculation of Relative Quantification (RQ) (relative expression):

After the RT-PCR will run, the data will be expressed in Cycle threshold (Ct).PCR data sheets will include Ct values of assessed gene and the house keeping (reference) gene which will be continuously expressed in the cell- (β-actin).To measure the gene expression of certain gene, -ve control sample shall be used. So target gene expression will be assessed and related to reference (internal control) gene as follows:

Finally, RQ was calculated according to the following equation:

  1. ∆ Ct (Cycle threshold) = Ct assessed gene - Ct reference gene
  2. ∆∆ Ct = ∆ Ct sample - Ct control gene
  3. RQ = 2-(∆∆Ct)

干预措施: Bmi-1 antibody (Diagnostic Test)

结局指标

主要结局

oral squamous cell carcinoma

时间窗: 10 months

Different grades of oral squamous cell carcinoma

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Asmaa Mohamed Abo Gabal

teaching assistant

Cairo University

研究点 (1)

Loading locations...

相似试验

已完成
不适用
Integrative Multi-Omics Testing for Immunotherapy Response in Non-Small Cell Lung CancerLung Cancer
NCT05928299Nanfang Hospital, Southern Medical University150
已完成
不适用
Rapid Diagnostic Test for Septic ArthritisArthritis, SepticArthritis, UnspecifiedJuvenile Idiopathic Arthritis
NCT04460144Assistance Publique - Hôpitaux de Paris274
已完成
早期 1 期
Matrix Metalloproteinase-1/Tissue Inhibitor of Metalloproteinase-1 (MMP-1/TIMP-1) Ratio and Diabetic Foot UlcersDiabetic Foot Ulcer
NCT00935051University Hospital, Grenoble59
进行中(未招募)
不适用
Evaluación mediante proteómica de biomarcadores proteicos asociados con el tratamiento con Eplerenona versus espironolactona en pacientes post-infarto agudo de miocardio, diabéticos con hipertensión arterial no controlada y disfunción ventricular sistólica leve”Identification of proteomic biomarkers associated with eplerenone treatment versus spironolactone in post-acute coronary syndrome patients, with non-controlled arterial hypertension and ventricular dysfunction - PROMETEODisfunción ventricular leve-moderada post-infarto agudo de miocardio en pacientes diabéticos con hipertensión arterial no controlada.Low-moderate ventricular dysfunction in post-acute coronary syndrome patients with diabetes and non-controlled arterial hypertension.
EUCTR2008-001192-29-ESFundación Investigación y Desarrollo en el Area Cardiovascular
已完成
不适用
Bipolar Proteomic Assay Validation StudyMajor Depressive Disorder, Bipolar I and Bipolar II
NCT02746367Myriad Genetic Laboratories, Inc.261